MENU
SBIO
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

SBIO stock forecast, quote, news & analysis

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index... Show more

Category: #Health
SBIO
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for SBIO with price predictions
Jul 24, 2026

SBIO's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for SBIO moved out of overbought territory on July 13, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 instances where the indicator moved out of the overbought zone. In of the 30 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SBIO as a result. In of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SBIO turned negative on July 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

SBIO broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

SBIO moved above its 50-day moving average on June 17, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SBIO crossed bullishly above the 50-day moving average on June 24, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBIO advanced for three days, in of 311 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 225 cases where SBIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX).

Industry description

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.

Market Cap

The average market capitalization across the ALPS Medical Breakthroughs ETF ETF is 2.96B. The market cap for tickers in the group ranges from 67.49M to 12.4B. AXSM holds the highest valuation in this group at 12.4B. The lowest valued company is PLRX at 67.49M.

High and low price notable news

The average weekly price growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was -2%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was 21%. XNCR experienced the highest price growth at 11%, while MGNX experienced the biggest fall at -18%.

Volume

The average weekly volume growth across all stocks in the ALPS Medical Breakthroughs ETF ETF was -9%. For the same stocks of the ETF, the average monthly volume growth was -61% and the average quarterly volume growth was -51%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 77
Price Growth Rating: 48
SMR Rating: 93
Profit Risk Rating: 81
Seasonality Score: 13 (-100 ... +100)
View a ticker or compare two or three
SBIO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
ALPS ETFPO Box 328Denver
Phone
855.724.0450
Web
www.alpsfunds.com
SBIO's RSI Oscillator recovers from overbought zone